Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ VNDA opened at $4.85 on Friday. Vanda Pharmaceuticals has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The business has a 50 day moving average price of $4.88 and a two-hundred day moving average price of $5.14. The firm has a market cap of $282.79 million, a PE ratio of -17.32 and a beta of 0.77.

Insider Transactions at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals in the third quarter valued at $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the period. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $75,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth about $84,000. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.